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 A major portion of pain experienced by patients with an Irritable Bowel Disease (IBD) or 
Irritable Bowel Syndrome (IBS) can be attributed to visceral hypersensitivity. Visceral stimuli 
transmitted through primary afferent neurons in the dorsal root ganglia (DRG) induce a 
nociceptive response. Notably, a subset of patients have also experienced the development of 
somatic pain, such as leg pain, after diagnosis of a bowel disorder. The aim of this investigation 
is to ascertain which biochemical mediators are involved in the development of such 
 vi 
viscerosomatic cross-sensitization. Initially, the Von Frey Test was used to find behavioral 
evidence of somatic referred pain; TNBS-induced mice exhibited a greater withdrawal response 
to hindpaw stimulation than control mice. Then, fast blue retrograde tracing was conducted and 
hindpaw innervation was identified to occur via primary afferent neurons located in the DRG at 
L4 spinal level. Immunohistochemical studies were conducted on L4 DRG tissue to evaluate 
levels of cellular mediators known to be involved in pain signaling, such as phosphor(p)-Akt. L4 
DRG from TNBS-treated mice exhibited significantly higher levels of phospho-Akt 
than control animals. The increased p-Akt was located in Piezo2-expressing L4 DRG neurons 
and was suppressed in mice lacking TrkB.T1. These findings suggest that the PI3K/Akt pathway 
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1.1 Inflammatory Bowel Disease 
Inflammatory Bowel Diseases are characterized by inflammation and disruption within 
the gastrointestinal tract. The prevalence of IBD in North America and Europe has been a 
significant problem and it continues to grow due to a young age of onset and low mortality (1). 
Cases are rapidly increasing in newly industrialized countries around the world, particularly in 
Asia, Africa, and South America. Studies reveal that there is no significant difference in IBD 
cases amongst men and women, and there also does not seem to be significant variation by race 
(2). Early onset of this disease is fairly common; previous findings by McDowell et al. estimate 
that up to a fourth of patients may develop IBD by adolescence. A 2019 study approximated that 
2 million people have been affected by IBD in North America, and that this number is projected 
to double by 2030 (3). In terms of financial cost, this disease was expected to cost the healthcare 
systems of the United States and Canada around 10 billion US dollars as of 2018 (3). Given the 
increasing prevalence around the world and the projected population affected, this disease can 
become a significant global burden. When considering the future, the early onset of IBD may 
also present complex cases/comorbidities due to longer disease duration (1). 
IBDs can be differentiated into two types: Crohn’s Disease (CD) or Ulcerative Colitis (UC); 
if either of these cannot be confidently diagnosed, then the condition is considered IBD-
undifferentiated (IBD-U) (4). Common symptoms of IBDs in affected patients include diarrhea, 
abdominal pain, weight loss, and/or bloody stools (5). 
Crohn’s Disease (CD) can involve any aspect of the gastrointestinal tract ranging from the 
mouth to the anus. Most commonly, CD affects the ileum and/or the large intestine, generally in 
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a discontinuous pattern. The symptoms vary based on the location and severity of disease, 
resulting in varying clinical presentation from one patient to another. Common symptoms 
include abdominal pain, watery diarrhea, and weight loss. This pain is acute and severe, 
generally localizing to the right lower quadrant (5). The abdominal pain and the diarrhea tend to 
be episodic and can occur intermittently for years prior to diagnosis. A key feature of Crohn’s is 
that it affects all layers of the bowel (1), potentially leading to strictures or fistulas. CD can cause 
serious problems for the skin and also lead to biliary stones over time (2). Systemic symptoms 
can also be seen due to CD, with fatigue being the most common (due to persistent inflammation 
and malabsorption) (5). 
Ulcerative Colitis (UC) generally involves inflammation confined to the colon, and 
therefore symptoms are not as diverse as those in CD (4, 8). The inflammation tends to start in 
the rectum and spreads in a continuous pattern towards the proximal colon. While the large 
intestine gets inflamed, the small intestine continues to function normally (7). In contrast with 
CD, UC only affects the innermost layer of the colon or other affected areas. UC frequently 
presents as bloody diarrhea, and patients often describe tenesmus, a sensation of incomplete 
emptying. The extent of blood present in the stool can be indicative of the severity of disease (8). 
Physical exams often reveal left lower or upper quadrant abdominal pain. If UC lasts for 8-10 
years, it can lead to osteoporosis or even colon cancer. With longer disease courses, patients may 
also develop colonic strictures which cause obstruction/pain (8). 
The cause of IBDs continues to be a mystery; various factors seem to be involved, but 
there has not been a universal aspect which is consistent among all patients. Genetic and 
environmental factors are certainly involved, and patients with compromised or inappropriate 
immune responses are particularly susceptible (6, 7). Recent Genome wide association studies 
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(GWAS) have revealed 240 nonoverlapping genetic loci, of which 30 are common to both UC 
and CD. Analysis of these loci indicate their role in important pathways for intestinal 
homeostasis (5). Environmentally, the intestinal microbiota is the major driver of IBD; the gut 
bacteria affect the immune system, host metabolism, and GI development in major ways. 
The goal of treatment is to induce remission of IBD, and it varies based on the severity of the 
disease. Nonbiological therapies such as aminosalicylates, thiopurines, and steroids provide 
symptomatic relief but do not change the long-term course of disease progression. Biological 
therapies involving immunomodulators, such as tumor necrosis factor-a (TNF-a) antibodies, 
have induced or maintained remission in certain patients, but a significant portion of IBD 
patients were or became non-responders to this treatment; new methods of treatment targeting 
specific pathways have become increasingly necessary (9). 
 
1.2 Visceral Hypersensitivity 
While the inflammation in IBD is considered to be more severe than that in IBS, a recent 
study noted that there can be a significant amount of overlap in symptoms; up to 40% of IBS 
symptoms were present in patients with IBS and IBD (10). One of the primary symptoms, 
abdominal pain, is present in a plethora of gastrointestinal disorders. This pain may be due to 
visceral hypersensitivity; visceral hypersensitivity is defined as enhanced perception of 
mechanical triggers applied to the bowels (14). Such improper signaling of the viscera through a 
signaling reflex pathway is known to occur in both IBD and IBS, and may be affecting up to 
20% of the global population (11). There are two types of hypersensitivity: hyperalgesia and 
allodynia. Hyperalgesia is when there is an intensified pain sensation in response to stimuli 
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which usually provoke pain. Allodynia is when there is nociceptive sensation in response to 
normal stimuli (12). 
The sensory pathway through which visceral hypersensitivity occurs is known as the 
“gut-brain axis,” with signals going from the periphery to the central nervous system (13). 
Perceivable sensations, such as pain, in the colon and rectum are generated by extrinsic afferent 
neurons (13, 15). The conscious perception of pain/discomfort in the viscera occurs is signaled to 
the brain via these neurons, which respond to noxious mechanical stimuli. These neurons can be 
subdivided by the location of soma; splanchnic nerve cell bodies are located within the 
thoracolumbar dorsal root ganglion (DRG), and pelvic nerve cell bodies are within the 
lumbosacral DRG. DRGs are groups of cells bodies 
located all along the human body and convey sensory 
information from the Peripheral Nervous System (PNS) to 
the Central Nervous System (CNS). Each DRG is 
composed of a cluster of pseudounipolar neurons whose 
axons project onto the spinal cord transmitting the sensory 
signal towards the brain (16). In particular, these neurons 
are known to control our sensation of pain and 
temperature; for this reason, they have immense potential 
as targets in the treatment of chronic pain. Colonic 
innervation occurs primarily through the thoracolumbar spinal cord with the signal relaying 
through the splanchnic nerves. Rectal innervation is mainly thought to transmit signals through 
the lumbosacral spinal cord via the pelvic nerves. Peripheral portions of the afferents in the DRG 
Figure 1: Visceral Organ Sensation. Visceral 
organs are innervated by pseudounipolar neurons, or 
primary afferent neurons, which transmit onto 
second order neurons in the spinal cord. These 
second order neurons then convey sensory 
information to the brain. 
 6 
innervating the colorectum then terminate onto second order neurons in the dorsal horns of 
vertebrae in the spinal cord which transmit the signal to the brain (13, 17).  
In the mouse colon, eight different types of afferent fibers have been identified and five 
of these have also been recorded in humans: mucosal afferents, muscular afferents, 
muscular/mucosal afferents, vascular endings, and silent afferents (13, 18). Mucosal afferents 
have low thresholds for activation, responding mainly to distortion of the colonic mucosal 
epithelium. Muscular afferents have low distention thresholds in response to the colorectum, and 
likely contribute to nociception when there is high stimulus intensity. Muscular/mucosal 
afferents respond to mucosal distortion and circular stretch and aren’t found in splanchnic 
innervation of the distal colon. Vascular endings wrap around blood vessels in the mesentery and 
submucosa and have the greatest similarity to cutaneous nociceptors. These afferents respond to 
high-threshold stimuli, inflammatory/immune mediators, and also noxious distention. The last 
group of afferents discussed are mechanically insensitive or “silent” in normal conditions. Three 
different types of silent afferents have been identified: those that respond to chemical stimuli 
(inflammatory markers) and do not develop mechanical sensitivity, those who develop 
mechanical but not chemical sensitivity, and finally those stimulated chemically and 
mechanically. (18) 
Ultimately, both low threshold and high threshold mechanosensitive afferents are 
affected during sensitization and contribute to pain/discomfort; this response can be further 
amplified by the recruitment of silent afferents capable of developing mechanosensitivity (13). 
Inflammation leads to increased signal intensity and frequency, along with lower thresholds of 
activation for these afferent neurons. Experiments comparing control and viscerally inflamed 
mice showed an increase in mechanosensitive afferents with a near equivalent decrease in silent 
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afferents. In mice exposed to conditions of hypersensitivity for 3 consecutive days, the 
proportions of mechanosensitive afferents remained higher for weeks after the inflammatory 
agent was last administered (19). The exact mechanism by which inflammation induces such 
changes in the extrinsic afferent fibers is still controversial; many chemical mediators may play a 
role, including but not limited to amines, peptides, cytokines, and neurotrophins. 
  Many scientists have attempted to better understand the mechanism of sensitization by 
inducing visceral pain in animal models. Although it is difficult for models to serve as a true 
representation of this condition in humans, previous studies with mice and rats show behavioral 
similarity to that of post-infectious IBS patients, who still perceive pain after inflammation has 
abated (20, 22). Inflammation is induced in these animals through the use of certain haptens, 
substances which cannot induce inflammation on their own, but cause an inflammatory response 
once attached to specific proteins. 2,4,6-trinitrobenzene sulfonic acid (TNBS) is a common 
hapten which has been shown to cause inflammation, peaking after 4-5 days and persisting 
around a month post-injection. Hypersensitivity in the treated persisted for up to 16 weeks after 
inflammation has ceased (21). 
 
1.3 Neurotrophin Signaling  
Neurotrophins are a group of proteins that are known for their role in embryonic 
development of the PNS and CNS (23). These proteins are essential for neuronal survival, 
proliferation, and regulation. Outside of their importance during the embryonic stages, 
neurotrophins, particularly nerve growth factor (NGF) and brain-derived neurotrophic factor 
(BDNF), play an important role in nociceptive signaling as well. Expression of four 
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neurotrophins has been identified in mammals: NGF, BDNF, neurotrophin-3 (NT-3), and 
neurotrophin-4 (NT-4) (24).  
These neurotrophins mediate cellular 
processes by binding to two types of receptors, 
Trk tyrosine kinase receptors and the p75NTR 
receptor (24). The Trk receptors each have high 
selectivity for specific neurotrophins; NGF binds 
to TrkA, BDNF and NT-4 bind to TrkB, and NT-
3 binds to TrkC. The p75NTR receptor can bind to 
all of the mammalian neurotrophins with low 
affinity (24, 25). The locations of both types of 
receptors are variable throughout the body and 
neurotrophin binding can affect cellular function in 
diverse ways. After binding, the 
neurotrophin/receptor complex is internalized by the cell and growth factor receptors maintain 
the signal from endosomes (26). Trk receptor signaling is known to promote cell proliferation 
through signaling including but not limited to the PI3K/Akt, MEK/MAPK pathways, and PLCg 
pathways (25). Meanwhile, the p75NTR receptor is capable of supporting or inhibiting cell 
proliferation. In neurons with both Trk and p75NTR receptors, their physical interaction can 
increase ligand affinity and delay degradation of the Trk receptor, prolonging the signal (24). 
The immature form of the neurotrophins, pro-neurotrophins, are also capable of binding to the 
p75NTR receptor when sortilin is present, leading to transmission of an apoptotic signal via the 
Jun kinase pathway (27). 
Figure 2: Neurotrophin Signaling Pathways. 
Neurotrophin binding to Trk receptors (orange) or 
p75NTR receptors (purple) set off signaling cascades 
promoting neuronal survival, synaptic plasticity, 
and/or cell growth. However, binding of pro-
neurotrophins to p75NTR receptor in the presence of 
sortillin (blue) leads to initiation of apoptotic signals.  
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1.4 BDNF and NGF 
As previously mentioned, BDNF and NGF play an important role in pain signaling. NGF 
has been found to increase activity of primary afferents through various mechanisms, while 
BDNF is more involved in central sensitization (25). In adulthood, NGF was originally thought 
to be a means of treating peripheral neuropathy due to its neurotrophic effects, but administration 
in clinical trials exacerbated the pain (28). Further experimentation supported this, as levels of 
NGF mRNA were elevated during inflammatory conditions (29). In regard to visceral pain, 
levels of colonic NGF expression in patients with IBS were positively associated with disease 
severity and gut barrier dysfunction (30). The augmented pain sensation in response to NGF may 
occur through various mechanisms: lower thresholds, increased recruitment, and/or increased 
transcription of the nociceptors (25). NGF signaling is also believed to play a role in the 
development of mechanosensitivity in silent afferents (31). Additionally, BDNF was found to be 
localized primarily in NGF-sensitive neurons expressing TrkA (32,33). BDNF protein is found to 
increase in response to nociceptor activity and can rapidly increase when there are high levels of 
NGF during inflammation. BDNF can also be released in response to mucosal NMDA receptor 
activation, which is known to be involved in visceral hypersensitivity; this increase in BDNF 
was found to occur via an Erk dependent pathway.  
Ultimately, there are various mechanisms through which neurotrophins can lead to the 
sensitization of DRG neurons. In TNBS-induced colitis, increased expression of the TRPV1 
receptor was noted in L1 and S1 level DRGs in conjunction with increased NGF expression; this 
increased expression also occurred with NGF treatment and was attributed to activation of the 
PI3K/Akt pathway (34). CGRP, an important nociceptive marker, also had elevated levels after 
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NGF treatment. CGRP is colocalized with TrkB in lumbar and sacral (L1 and S1 DRG), and 
increased CGRP expression correlated with BDNF activation (35). When given BDNF 
treatment, increased amount and density of CGRP fibers were also noted. Therefore, NGF may 
upregulate BDNF expression, which goes on to upregulate CGRP expression. Further analysis 
revealed that this upregulation occurs through the PLCg pathway downstream of BDNF-TrkB, 
and the Mek/Erk and PI3K/Akt pathways were not involved (25). Another important molecule, 
cAMP-responsive element binding (CREB) protein, was also activated in the neurons which 
showed upregulation of CGRP. The involvement of this molecule was confirmed by BDNF 
antibody treatment, which attenuated the CREB activation (36). Our growing understanding of 
these signaling cascades sheds light on the complexity of visceral hypersensitivity, and also on 
which molecules may be worthy targets in medicine. 
	
1.5 Cross-Sensitization 
 Pain from visceral organs tends to be diffuse and poorly localized, and also can be 
associated with somatic pain elsewhere. This “referred” pain has been recognized in numerous 
conditions affecting different organs. Such cross-sensitization has been seen in patients between 
the stomach and heart, esophagus and heart, colon and urinary bladder, and many other organ 
pairings (37). Patients with gastrointestinal conditions often concurrently have comorbidities like 
bladder disorders, neck pain, foot pain, etc. The inflammation or damage originating in the GI 
system from a certain organ led to sensitization elsewhere in response to certain stimuli. One 
clinical survey revealed that patients with chronic bladder pain are up to 100 times more likely to 
have IBD relative to the general population (38, 39). 
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The development of cross-sensitization is not yet fully understood, and further studies 
exploring the pathogenesis of cross-sensitization require an animal model which develops similar 
symptoms as those in humans. The rodent TNBS-induced colitis model has shown promise, as 
rodents in these conditions have shown bladder hypersensitivity and somatic pain in response to 
mechanical stimulation (40). Additionally, rodents are known to have similar neuron-cell 
interactions to humans in terms of pain sensation. When considering the mechanism by which 
cross-sensitization occurs, interactions among primary afferent neurons and non-neuronal cells 
are considered as major players (37). One afferent neuron is generally surrounded by two or 
three satellite glial cells (SGCs), and colitis 
has led to increased coupling between SGCs 
around colonic afferents (41). The afferent 
neuron may then release cellular mediators 
which transmit the signal to SGCs. The 
SGCs then may communicate with SGCs 
surrounding another afferent neuron via gap 
junctions, allowing for transmission of 
nociceptive signals among neurons within 
DRG that innervate different organs. For 
cross-sensitization between organs which are 
not innervated by DRG neurons in the same 
spinal segment, it can likely be attributed to 
communication between DRG through the spinal cord. A recent study showed that TNBS-
induced mice developed somatic heterosegmental and homogesegmental hypersensitivity to the 
Figure 3: Mouse Model of Cross-Sensitization. Colonic 
inflammation leads to increased coupling of SGC and 
accumulation of macrophages due to nociceptive signaling from 
the neuron. This nociceptive signaling can be transmitted to 
heterosegmental afferents via microglia-astrocyte networks in the 
spinal cord. 
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hindpaw and low back, respectively (42). Colororectal innervation was traced to L6, low-back 
innervation was also in L6, and hindpaw innervation was traced to L4. TNBS treatment led to 
hypersensitivity to somatic regions innervated by neurons within the same DRG and to those 
innervated by a distinct spinal region in L4 (42). The central sensitization likely triggered by the 
release of mediators into the spinal cord (43). The central response to these mediators is 
bolstered by activation of microglia and astrocytes in the spinal cord, which are upregulated 
following colitis (37,44). Astrocyte networks then may convey this signal from DRG at one level 
to another (Figure 3). Understanding the interactions of the sensory neuron and glial cells  in the 
primary afferent pathway, and also the biochemical mediators involved in the signaling will be 
very important in the path towards mitigating such referred pain. 
 
1.6 TrkB.T1 
TrkB.T1 is a truncated isoform of the TrkB receptor. This isoform is known to be 
upregulated during fetal growth and becomes one of the common Trk receptor isoforms present 
in adults (48). TrkB.T1 deficient mice were noted to be able to develop normally, but exhibited 
anxious behaviors more often than control animals and had neuronal abnormalities in the 
amygdala. Recent studies indicate that the TrkB.T1 receptor may actually have a maladaptive 
role in response to disease or injury (49). Specifically, TrkB.T1 receptors are increased in SGCs 
after peripheral inflammation, maintaining BDNF signaling. This receptor isoform has also been 
found to induce astrocytic morphogenesis in response to BDNF, and astrocyte networks play a 
key role in central sensitization post-inflammation (37). TrkB.T1 therefore carries potential as a 




 Akt is a serine/threonine protein kinase involved in various cellular processes, primarily 
to support cell survival/proliferation. Activity of Akt is regulated by post-translational 
modifications, such as phosphorylation or ubiquitination. Phosphorylation of Akt by a kinase 
leads to its activation, while dephosphorylation via a phosphatase can be a means of regulation. 
Additionally, Akt is known to promote survival through inhibition of apoptotic processes and is 
therefore implicated in various types of cancer (45). Akt can be activated by multiple factors 
such as cytokines, growth factors and neurotrophins. Growing evidence shows that Akt also 
participates in the processes of visceral hypersensitivity and somatic pain. For example, an Akt 
inhibitor was able to block the NGF upregulation which occurred during gastric hypersensitivity 
(46). TRPV1 upregulation, which was noted to occur with TNBS-induced colitis, involved the 
PI3K/Akt pathway (34). TNBS-induced colitis models also have shown evidence of CGRP 
triggering an increase in Akt phosphorylation, which leads to central sensitization and allows for 
crosstalk between segments along the spinal cord (47). 
 
1.8 Piezo2 
The Piezo channel family has been evolutionarily conserved and play a vital role in the 
mechanotransducive processes of different cell types (50). Piezo2, in particular, is known to be 
involved in touch sensation, respiration and proprioception. Piezo2 deficient mice have been 
noted as unable to sense discriminative touch (51). Piezo2 plays a role in sensory pathways and 
has specifically been localized in sensory neurons of DRG and marks neurons that respond to 
mechanical stimulation (52). It’s role in pain has become clearer with time, and the expression of 
this channel has notably increased in nerve-injury induced mechanical pain (51). When 
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considering visceral hypersensitivity, a former study showed that Piezo2 knockdown in the DRG 
resulted in attenuation of visceral sensation to innocuous or noxious stimuli (53).  
 
1.9 Summary 
 Previous studies indicate that TNBS-induced inflammation can lead to referred somatic 
pain innervated by a DRG heterosegmental to the DRG innervating the colorectum. However, 
the cellular mediators and mechanism(s) by which this can occur are understudied. The goal of 
this study is to characterize the expression of p-Akt in L4 DRG following colitis induction and 
the regulation of p-Akt by TrkB.T1-mediated cellular events in order to understand the molecular 











 The objective of this study is to ascertain which signaling pathway may be involved in 
the development of referred somatic pain resulting from viscerosomatic cross-sensitization. 
 
Hypothesis 
 TNBS-induced inflammation leads to somatic hypersensitivity which is associated with 
changes in neurochemical coding in L4 DRG and is regulated by BDNF/TrkB.T1.  
 
Aims: 
Aim 1: Establish behavior evidence of somatic hypersensitivity developing after induction of 
visceral inflammation 
Aim 2: Determine which group of afferent neurons (DRG) innervate the affected somatic region  









 Adult Black 6 male mice weighing 25-30 grams were used for all studies All 
experimental protocols involving animal use were approved by the Institutional animal Care and 
Use Committee at the Virginia Commonwealth University (IACUC# AM10315). Animal Care 
was in accordance with the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) and National Institutes of health guidelines. All efforts were made to minimize 
the potential for animal pain, stress, or distress as well as to reduce the number of animals used. 
 
Introduction of Colonic Inflammation in Mice with TNBS 
Under anesthesia (2.5 % isoflurane), a single dose of TNBS (75 µL of 12.5 µg/µL TNBS 
in 30 % EtOH) was administered into the mouse colon via a polyethylene (PE)-50 catheter 
through the anus. The proximal tip of the catheter was 2.5 cm inside from the anus. The mouse 
tail was lifted for 1 min after TNBS installation to avoid drug leakage from the anus. The same 
amount of 30 % EtOH as vehicle was used in control animals. TNBS-treated mice developed 
peak colonic inflammation on day 3-4 and persistent visceral hypersensitivity after inflammation 
resolution (> 7 days) [9,12,19]. 
 
Von Frey Test 
The mice were placed individually into cages with a mesh floor underneath. They were 
then allowed to acclimatize to their environment for 30 minutes. After this period, a 
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microfilament was applied perpendicularly to the plantar surface of the hindpaw when the animal 
has all four paws resting on the floor. The responses were recorded in a treatment blind manner, 
with a response considered as positive if a withdrawal behavior (paw licking, shaking, or 
withdrawal) was noted during or immediately after application. The mice were each 
consecutively tested for a filament size, and this was repeated five times before moving on to a 
filament size of higher force. These tests were conducted 1 week, 2 weeks and 3 weeks post-
injection. More than one animal was used for each experimental group to show variability. 
 
Perfusion and tissue dissection 
Animals were put under anesthesia (2.5% isoflurane) in an induction chamber. The mouse was 
then kept under anesthesia, and a lateral incision was made through the integument and 
abdominal wall. A small incision was then made in the diaphragm along the entire length of the 
rib cage to expose the pleural cavity. Tissue surrounding the heart was trimmed away, and 
another incision was made to the animal’s right atrium. A needle was then secured into the 
posterior end of the left ventricle, at which point the mouse was perfused with Krebs Buffer to 
flush out blood. After the fluid became clear, the buffer valve was switched to administer the 
fixative buffer, 4% paraformaldehyde (PFA). The valve was then closed once the fixative was 
nearly finished and the mouse became stiff. Next, an incision was made to the back to expose the 
spinal column, which was then isolated from the animal. Muscle, fat, and soft tissues were then 
trimmed away from the column, and DRG were collected and stored in 4% PFA for 2 hours. 




Fast Blue administration 
Under anesthesia (2.5% isoflurane), mice were administered Fast Blue in the plantar 
surface of their hindpaw to retrogradely label the primary afferents responsible for hindpaw 
sensation. DRG tissues from T13, L1, L2, L3, L4, L5, L6, and S1 were collected 1 week post-
Fast Blue administration, after which the mice went through whole-body perfusion as previously 
mentioned. After dissection, the DRG were kept in 4% paraformaldehyde for 2 hours and then 
stored in 20% sucrose overnight. Each DRG was then embedded in OCT cryostat medium 
(Tissue Tek), sectioned at 10 µm thickness, and placed on gelatin coated slides for examination 
in a microscope. 
 
Immunohistochemistry 
The DRG were taken out from 20% sucrose and embedded in OCT cryostat medium 
(Tissue Tek). Each ganglion was then sectioned at 10 µm thickness and placed on gelatin-coated 
slides. Slides were then heated at 35° for 15-30 minutes or until the sections were no longer 
frozen. A hydrophobic border was then placed around the slide using a Pap Pen prior to 
application of the primary antibody solution. Slides were then incubated overnight with specific 
primary antibody at room temperature in 2% Normal Donkey Serum and 0.3% Triton Buffer. 
Following incubation, slides were washed with a 0.1M sodium phosphate buffer at a pH of 7.4 
for ten minutes three times. Slides were then incubated with a fluorescent species-specific 
secondary antibody for two hours. The slides were then washed again with 0.1M sodium 
phosphate buffer three times for ten minutes each. Citiflour anti-fadent mounting medium 
(Electron microscopy Science) was then added onto the slides before placement of the cover 
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slips. Slides were viewed with an Axiocam Carl Zeiss microscope and neurons exhibiting 
immunoreactivity greater than the background level were considered positively stained. 
 
Transgenic mice 
       Piezo2 reporter mice were generated by crossing Piezo2EGFP-IRES-Cre mice (Jax Stock 
No. 027719) with R26-LSL-Gi-DREADD (Jax Stock No. 026219) so that Piezo2-expressing 
cells can be visualized by mCitrine yellow fluorescent protein (YFP). TrkB.T1 global knockout 
mice were obtained from NIH/NCI and a gift from Dr. Lino Tessarollo. All these transgenic 
mice received TNBS treatment in parallel to wildtype mice.  
  
Immunohistochemical Analysis 
DRG cells exhibiting immunoreactivity greater than the observed background level were 
considered positively stained. The number of positive cells in an area of the DRG were then 
counted. The overall area was also measure excluding areas with no cells and/or with nerve 
fibers. The area was converted from units of (µm^2) to units of (mm^2), and the cells per area 
(mm^2) were then calculated. 
 
Statistical Analysis 
 Results of each study were shown as the mean ± SEM. Multiple groups were compared 
by ANOVA with differences between means considered significant at p£ 0.05. When two groups 




















Figure 4: Von Frey Test. TNBS-induced and control animals were placed in cages with a mesh 
floor underneath a designated time post-injection. After a 30 minute acclimatization period, their 
somatic sensitivity was tested by mechanical stimulation of a hindpaw with Von Frey filaments 




















Figure 5: Fast Blue Retrograde Tracing. Mice were administered Fast Blue, and DRG tissues 





























Figure 6: Immunohistochemistry Design. L4 DRG of control and TNBS-administered mice 
were dissected 2 weeks post-injection. After collection of L4 DRG tissues, 
































4.1 TNBS-induced mice develop somatic hypersensitivity which peaks 2 weeks post-TNBS 
administration 
 1 week-post TNBS administration, TNBS treated mice began to exhibit a higher number 
of withdrawal responses relative to control mice once filaments of 0.04-1.0 grams-force were 
applied. 2 weeks-post TNBS administration, the treated mice exhibited a higher number of 
withdrawal responses at 0.04-1.0 grams-force than the previous week, and still more than control 
mice. 3 weeks-post administration the treated and control mice began to have a similar number 
of withdrawal responses (Figure 7). These results were obtained from two animals per 
experimental group. 
 
4.2 Fast Blue Retrograde tracing revealed that sensory afferents innervating the hindpaws 
are localized in L4 DRG 
 Tissue analysis was conducted 1 week post-Fast Blue administration to the hindpaw, and 
DRG tissue (T13, L1, L2, L3, L4, L5, L6, and S1) dissection revealed evidence of fast blue 
primarily in neurons of DRG at spinal levels L4, L5 and L6. Of those, L4 had a significantly 
higher number of neuronal cells exhibiting presence of the fast blue dye (p<0.05). These results 
were obtained from 4 paws of 2 animals (Figure 8). 
 
4.3  The PI3K/Akt pathway is activated in TNBS-induced somatic hypersensitivity 
 Immunohistochemical studies were conducted to characterize the role of the PI3K/Akt 
pathway in development of referred somatic pain. Analysis of images showed that TNBS-treated 
mice exhibited significantly higher levels of p-Akt in L4 DRG than control mice (p<0.05). These 
results were obtained using 6 animals per experimental group (Figure 9). 
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4.4 Increased p-Akt co-expression in Piezo2 labeled cells in L4 DRG of TNBS-treated mice 
 P-Akt colocalization was analyzed in control and TNBS treated Piezo-YFP labeled 
transgenic mice to investigate the involvement of Akt activation in mechanical sensitization. 
Findings suggest that the TNBS treated transgenic mouse had greater p-Akt and Piezo 
colocalization than the control transgenic animal. These results were obtained with one animal 
per experimental group (Figures 10 and 11).  
 
4.5 TrkB.T1 KO attenuates TNBS-induced increase in p-Akt levels in L4 DRG 
 In order to further distinguish the involvement of the PI3K/Akt pathway in cross-
sensitization further immunochemistry was conducted with control, TNBS, and TNBS + 
TrkB.T1 KO mice. Immunohistochemical analysis revealed that p-Akt levels in the L4 DRG of 
TrkB.T1 KO mice are significantly lower than those in the L4 DRG of TNBS treated mice 
(p<0.05).  These results were obtained with 6 animals for the control and TNBS treatment 




















Figure 7: Von Frey Test for Mechanical Sensitivity. Graphs display the number of times out 
of 5 that each mouse exhibited withdrawal response to stimulation for increasing filament sizes 
(n=2 for both experimental groups) at A. 1 week post-TNBS or saline administration B. 2 weeks 

















































































































Figure 8: Fast Blue Retrograde Tracing.  A. Imaging of L4 DRG containing Fast Blue Dye, 
red arrows point to cells positive for Fast Blue dye B. Imaging of sections from each DRG reveal 

































































Figure 9: Changes in p-Akt levels after TNBS-induced inflammation.    A. Images of control 
versus TNBS-treated DRG   B. Enlarged image of TNBS treated L4 DRG with arrows pointing 
to positively stained cells     C. TNBS-treated mice have increased levels of p-Akt in L4 DRG 




























































Figure 10: p-Akt expression in Piezo-YFP labeled DRG cells.     A. Images showing sections 
of control L4 DRG with Piezo-YFP (green), p-Akt (red), and their colocalization with arrows 
pointing to positive cells B. Images showing sections of TNBS-treated L4 DRG with Piezo-YFP 



























































Figure 11: Percentage of Piezo2 cells expressing p-Akt.    A.  Enlarged images of merged 
control and TNBS-treated L4 DRG, with arrows pointing to cells positive for p-Akt and Piezo 
colocalization.     B. Percentage of Piezo-YFP cells expressing p-Akt increases in TNBS-treated 
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Figure 12: Effect of TrkB.T1 KO on p-Akt expression after TNBS induced inflammation.       
A. Images of L4 DRG from control, TNBS treated, and TNBS + TrkB.T1 KO.     B. The increase 
in p-Akt levels in TNBS treated mice is attenuated by TrkB.T1 KO (Control and TNBS: n=6, 























































Inflammatory Bowel Disease (IBD) is a chronic disease affecting millions of people 
around the world and its prevalence continues to grow.  A major contributor to a patient’s 
discomfort is visceral hypersensitivity, which is also experienced by patients with Irritable 
Bowel Syndrome (IBS).  This hypersensitization is attributed to increased inflammatory 
signaling from primary afferent neurons in the dorsal root ganglion (DRG), and various changes 
in afferent signaling can lead to the persistence of sensitization. Additionally, a subset of patients 
with IBD or IBS report development of referred somatic pain, such as neck pain or leg pain, 
adding to their discomfort (54). The goal of this study is to investigate the underlying cellular 
mediators which may facilitate the development of such viscerosomatic cross-sensitivity.  
         In this study, Von Frey tests exhibited that 2,4,6-trinitrobenzene sulfonic acid (TNBS) 
treated mice began to show mechanical hypersensitivity after one week, and that hypersensitivity 
peaked two weeks after TNBS administration. Of note, TNBS treated mice also exhibited 
agitative behavior by attempting to ram their heads into the top of the cage two weeks post-
injection, and this was not observed in the control mice. After three weeks, the behavior of the 
treated mice in response to mechanical stimulation indicated attenuation of their hindpaw 
hypersensitivity. Retrograde Fast Blue tracing showed that hindpaw innervation primarily takes 
place through sensory afferents in the L4 dorsal root ganglion (DRG), and this is supported by 
findings in a previous study (42). 
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         Immunohistochemistry conducted on L4 DRG revealed that phospho-Akt levels were 
higher in TNBS-treated mice compared to the control, suggesting that the PI3K/Akt pathway is 
involved in signaling from visceral afferent neurons to those innervating the hindpaw. Previous 
studies show that an increase in Akt phosphorylation has been noted to occur in L6 DRG of mice 
with TNBS-induced colitis and the activation of the PI3K/Akt pathway is believed to play a role 
in spinal central sensitization (37). The increase of phospho-Akt in L4 DRG of TNBS-treated 
mice noted in this study emphasizes the importance of the PI3K/Akt pathway in spinal cord 
sensitization and heterosegmental cross-talk. Additionally, colocalization of phospho-Akt and 
Piezo2 was noted to increase in TNBS-treated animals. Piezo2 is an important gated ion channel 
expressed by a portion of sensory neurons and is vital for touch sensation. The expression of this 
channel has been noted to increase in inflammatory conditions, and studies have shown Piezo2 to 
be a mediator of mechanical sensitization (51). Therefore, the increased colocalization of Piezo2 
and phospho-Akt in TNBS-treated mice further supports the role of the PI3K/Akt pathway in 
referred somatic pain. 
         The increase in phospho-Akt levels in TNBS-treated mice was found to be partially 
attenuated in TNBS-treated TrkB.T1 knockout mice. The TrkB.T1 receptor is a truncated form 
of the TrkB receptor and has a high affinity for BDNF (37). This receptor is upregulated in 
satellite glial cells (SGCs) during peripheral inflammation, ensuring response to BDNF 
signaling. The attenuation of phospho-Akt levels in TNBS-treated TrkB.T1 knockout mice 
indicates that glial cells (SGCs and astrocytes) play a role in somatic hypersensitization. Previous 
studies examining induced cross-sensitization, specifically of the colon and bladder, have shown 
that microglia and astrocytes are upregulated in response to inflammation (37,44). These cells 
start to show high expression of BDNF receptors, and astrocytic TrkB.T1 receptors are known to 
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induce morphogenesis upon activation. The BDNF increase in sensory neurons can release to the 
spinal cord therefore inducing increased levels of astrocytes and microglia in the spinal cord, and 
activation of TrkB.T1 receptors in these non-neuronal cells may allow for the transmission of 
nociceptive signaling to a distinct DRG via Akt activation. 
In conclusion, our findings show that the PI3K/Akt pathway plays a central role in 
viscerosomatic cross-sensitization. Akt activation is noted to increase in Piezo2 labeled cells, 
which may be a response indicative of the TNBS-induced somatic mechanical hypersensitivity. 
BDNF upregulation due to visceral inflammation leads to central sensitization, and activation of 
the PI3K/Akt pathway via TrkB.T1 receptors allows for the transmission of inflammatory signals 
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